YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer

• Status: Terminated
• Trial end date: 2004-02-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to determine the optimal dosage of YM598 for slowing down disease progression in patients with rising PSA after initial therapy for localized prostate cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Inc
• Collaborator: Astellas Pharma US, Inc.
• Treatments: N-(6-methoxy-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl)-2-phenylethenesulfonamide